These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 34750073)

  • 1. An industry survey of implementation strategies for clinical supply chain management of cell and gene therapies.
    Myles L; Church TD
    Cytotherapy; 2022 Mar; 24(3):344-355. PubMed ID: 34750073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects.
    Qiu T; Wang Y; Liang S; Han R; Toumi M
    Drug Discov Today; 2021 Oct; 26(10):2269-2281. PubMed ID: 33892148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decentralised manufacturing of cell and gene therapy products: Learning from other healthcare sectors.
    Harrison RP; Ruck S; Rafiq QA; Medcalf N
    Biotechnol Adv; 2018; 36(2):345-357. PubMed ID: 29278756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The comparability tales: A phase-appropriate roadmap for CGT drug product development.
    ; Clément N; Kassim SH; Leblanc D; Spink K; Tomtishen J
    Mol Ther Methods Clin Dev; 2024 Mar; 32(1):101170. PubMed ID: 38268743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transitioning from development to commercial: risk-based guidance for critical materials management in cell therapies.
    Scott M; Clarke D; Lipsitz Y; Brandwein H; Allickson J; Alzebdeh D; Aleksic S; Kraft C; Lhu L; Cornetta K
    Cytotherapy; 2020 Nov; 22(11):669-676. PubMed ID: 32713719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies.
    Nikiforow S; Frigault MJ; Frey NV; Gardner RA; Komanduri KV; Perales MA; Kebriaei P; Warkentin PI; Pasquini M; Aho JL; Levine BL; Heslop HE; Hlucky TL; Habucky K; Gharibo M; Jagasia M; Locke FL
    Transplant Cell Ther; 2023 Apr; 29(4):228-239. PubMed ID: 36709800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controls to Minimize Disruption of the Pharmaceutical Supply Chain During the COVID-19 Pandemic.
    Cundell T; Guilfoyle D; Kreil TR; Sawant A
    PDA J Pharm Sci Technol; 2020; 74(4):468-494. PubMed ID: 32467176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How do I structure logistic processes in preparation for outsourcing of cellular therapy manufacturing?
    Chen LN; Collins-Johnson N; Sapp N; Pickett A; West K; Stroncek DF; Panch SR
    Transfusion; 2019 Aug; 59(8):2506-2518. PubMed ID: 31135995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A quest for stakeholder synchronization in the CAR T-cell therapy supply chain.
    Holland SM; Sohal A; Nand AA; Hutmacher DW
    Front Bioeng Biotechnol; 2024; 12():1413688. PubMed ID: 39175619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multiscale simulation framework for the manufacturing facility and supply chain of autologous cell therapies.
    Wang K; Liu Y; Li J; Wang B; Bishop R; White C; Das A; Levine AD; Ho L; Levine BL; Fesnak AD
    Cytotherapy; 2019 Oct; 21(10):1081-1093. PubMed ID: 31445816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing a Blockchain-Based Supply Chain System for Advanced Therapies: Protocol for a Feasibility Study.
    Lam C; van Velthoven MH; Meinert E
    JMIR Res Protoc; 2020 Dec; 9(12):e17005. PubMed ID: 33315020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation Master Plans: Progress of Implementation in the Pharmaceutical Industry.
    Elser C; Richmond FJ
    Ther Innov Regul Sci; 2019 May; 53(3):354-363. PubMed ID: 29969918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicinal Product Development and Regulatory Agilities Implemented During the Early Phases of the COVID-19 Pandemic: Experiences and Implications for the Future-An Industry View.
    Geraci G; Bernat J; Rodier C; Acha V; Acquah J; Beakes-Read G
    Ther Innov Regul Sci; 2023 Sep; 57(5):940-951. PubMed ID: 37266868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scaling of cell and gene therapies to population.
    Knöbel S; Bosio A
    Handb Clin Neurol; 2024; 205():145-154. PubMed ID: 39341651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guidelines, editors, pharma and the biological paradigm shift.
    Singh AR; Singh SA
    Mens Sana Monogr; 2007 Jan; 5(1):27-30. PubMed ID: 22058616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variation in Medicaid and commercial coverage of cell and gene therapies.
    Beinfeld MT; Rucker JA; Jenkins NB; de Breed LA; Chambers JD
    Health Policy Open; 2023 Dec; 5():100103. PubMed ID: 38023441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical Care Network in the State of Qatar.
    Hijjeh M; Al Shaikh L; Alinier G; Selwood D; Malmstrom F; Hassan IF
    Qatar Med J; 2019; 2019(2):2. PubMed ID: 31763205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What Have We Learnt About the Sourcing of Personal Protective Equipment During Pandemics? Leadership and Management in Healthcare Supply Chain Management: A Scoping Review.
    Best S; Williams SJ
    Front Public Health; 2021; 9():765501. PubMed ID: 34957018
    [No Abstract]   [Full Text] [Related]  

  • 20. Will multi-industry supply chains' resilience under the impact of COVID-19 pandemic be different? A perspective from China's highway freight transport.
    Fu X; Qiang Y; Liu X; Jiang Y; Cui Z; Zhang D; Wang J
    Transp Policy (Oxf); 2022 Mar; 118():165-178. PubMed ID: 35125680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.